Is Mereo BioPharma now a hidden EU rare disease play with Ultragenyx exposure?

Mereo BioPharma Group plc (NASDAQ: MREO) is emerging as an under-the-radar beneficiary of the high-stakes osteogenesis imperfecta (OI) drug race, even as its partner Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) faces investor skepticism after a major trial update. The British rare disease-focused biopharmaceutical developer holds exclusive commercial rights to UX143 (setrusumab) in the European Union and United Kingdom, positioning it for potential royalty and direct sales revenue if final Phase 3 data confirm the drug’s efficacy. With Ultragenyx’s share price falling more than 25% after the Phase 3 Orbit trial failed to meet early stop criteria, investors may be overlooking Mereo’s longer-term upside embedded in its European rights and milestone-driven partnership terms.

The current collaboration agreement between Mereo BioPharma and Ultragenyx includes up to $245 million in milestone payments linked to development, regulatory, and commercial triggers, as well as royalties from Ultragenyx’s global territories outside the EU and UK. Mereo, in turn, will pay royalties to Ultragenyx on any future sales in its own markets. This structure allows the British developer to focus on its home commercial base while sharing late-stage development costs, which have been largely driven by Ultragenyx’s multi-country Orbit and Cosmic programs. For Mereo, which has faced historic volatility as a small-cap biotech, setrusumab’s potential success could transform it into a revenue-generating rare disease player in a market estimated to include 60,000 treatable patients.

How do Mereo BioPharma’s retained EU and UK rights change its long-term rare disease revenue outlook?

By retaining exclusive commercial rights in Europe, Mereo BioPharma positions itself to build a rare bone disorder franchise with a high barrier to entry. Unlike Ultragenyx, which shoulders the cost-intensive global program, Mereo will leverage data generated from the Orbit and Cosmic studies to seek regulatory approvals within the European Medicines Agency (EMA) and UK’s Medicines and Healthcare products Regulatory Agency (MHRA). Analysts suggest that European approvals for orphan-designated therapies tend to follow U.S. outcomes closely, particularly when supported by statistically significant fracture rate reduction and favorable safety profiles. The company’s ability to commercialize setrusumab independently, or to license its EU rights to a larger commercial partner, could drive material revenue inflection post-approval.

Setrusumab’s fully human monoclonal antibody design and sclerostin-inhibition mechanism have already been validated in Mereo’s adult Phase 2b ASTEROID study, which demonstrated dose-dependent improvements in bone mass and strength. This dataset provides strong groundwork for marketing to European rare disease specialists if pediatric Phase 3 data replicate the outcomes. Furthermore, OI currently has no approved disease-modifying therapies in Europe, creating an open field for a first-in-class agent. Industry experts argue that even modest fracture rate reductions could be commercially meaningful in a market where bisphosphonates remain the only widely used, albeit limited, therapeutic option.

Mereo also benefits from regulatory tailwinds. Setrusumab has already received Orphan Drug designation from the EMA and Breakthrough Therapy designation from the U.S. Food and Drug Administration, which could shorten approval timelines and confer market exclusivity in key European markets. Analysts view such designations as critical catalysts for small-cap biotech firms, as they enhance pricing power and investor confidence in post-approval uptake. In the EU, orphan drugs often achieve premium reimbursement levels, especially when addressing conditions with high unmet medical need like OI.

Industry observers note that Mereo BioPharma’s focused rare disease portfolio may give it a valuation advantage relative to diversified rare disease players. While Ultragenyx has multiple programs competing for investor attention, Mereo’s clinical pipeline—centered on setrusumab and its alpha-1 antitrypsin deficiency drug alvelestat—could allow it to scale strategically in the rare bone and lung disease segments. This leaner model may resonate with European institutional investors who prioritize high-margin orphan drug franchises with regional exclusivity. Some analysts believe that Mereo’s positioning could also attract future licensing or acquisition interest, particularly if larger European pharmaceutical companies seek to expand their rare disease portfolios without taking on global development risk.

The immediate challenge, however, lies in execution. Both the Orbit and Cosmic studies need to deliver compelling data not only on fracture rate reduction but also on functional mobility improvements, which are key to convincing European regulators and payers. Should final data meet these clinical endpoints, Mereo’s EU commercial rights would allow it to enter the market as the first disease-modifying treatment for OI, capturing early-mover advantage. Analysts suggest that even a conservative 10–15% penetration in accessible European markets could translate into significant revenue, given the high pricing potential for orphan drugs.

With Phase 3 data expected by year-end, Mereo BioPharma remains a speculative but increasingly interesting rare disease play. Its upside depends not only on Ultragenyx’s global execution but also on its ability to capitalize on its EU and UK rights. A positive data readout would unlock dual revenue streams—milestone payments from Ultragenyx and direct European commercialization—and could position the British biotech as a sought-after partner or acquisition target in the rare disease space.